BPTS - Biophytis and SEQENS will together produce Sarconeos active compound
2023-07-18 07:11:17 ET
Clinical-stage biotechnology company, Biophytis SA ( NASDAQ: BPTS ) and SEQENS concluded a master agreement for the production of the active compound in Sarconeos (BIO101), Biophytis' main drug candidate developed for three indications: severe forms of Covid-19, sarcopenia and Duchenne muscular dystrophy.
SEQENS will produce the active ingredient in Sarconeos in France at its Villeneuve La Garenne plant, near Paris.
This historic site was modernized and expanded in 2020 with the opening of a unit to produce high-potential active pharmaceutical ingredients.
For further details see:
Biophytis and SEQENS will together produce Sarconeos active compound